These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 29992836)

  • 1. Synthesis and evaluation of nitrofuranyl methyl N-heterocycles derivatives as novel antitubercular agents.
    Wang A; Li W; Wang B; Lv K; Wang H; Liu M; Guo H; Lu Y
    Future Med Chem; 2018 Sep; 10(17):2059-2068. PubMed ID: 29992836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and biological evaluation of nitrofuran-1,3,4-oxadiazole hybrids as new antitubercular agents.
    Wang A; Xu S; Chai Y; Xia G; Wang B; Lv K; Wang D; Qin X; Jiang B; Wu W; Liu M; Lu Y
    Bioorg Med Chem; 2022 Jan; 53():116529. PubMed ID: 34861474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents.
    Pieroni M; Wan B; Cho S; Franzblau SG; Costantino G
    Eur J Med Chem; 2014 Jan; 72():26-34. PubMed ID: 24333612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current development of 5-nitrofuran-2-yl derivatives as antitubercular agents.
    Elsaman T; Mohamed MS; Mohamed MA
    Bioorg Chem; 2019 Jul; 88():102969. PubMed ID: 31077910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conjugation of a 5-nitrofuran-2-oyl moiety to aminoalkylimidazoles produces non-toxic nitrofurans that are efficacious in vitro and in vivo against multidrug-resistant Mycobacterium tuberculosis.
    Krasavin M; Lukin A; Vedekhina T; Manicheva O; Dogonadze M; Vinogradova T; Zabolotnykh N; Rogacheva E; Kraeva L; Yablonsky P
    Eur J Med Chem; 2018 Sep; 157():1115-1126. PubMed ID: 30179748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of novel 2-aminothiazole conjugated nitrofuran as antitubercular and antibacterial agents.
    Ran K; Gao C; Deng H; Lei Q; You X; Wang N; Shi Y; Liu Z; Wei W; Peng C; Xiong L; Xiao K; Yu L
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3669-74. PubMed ID: 27289321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Naphthoquinones isolated from Diospyros anisandra exhibit potent activity against pan-resistant first-line drugs Mycobacterium tuberculosis strains.
    Uc-Cachón AH; Borges-Argáez R; Said-Fernández S; Vargas-Villarreal J; González-Salazar F; Méndez-González M; Cáceres-Farfán M; Molina-Salinas GM
    Pulm Pharmacol Ther; 2014 Feb; 27(1):114-20. PubMed ID: 23968826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, evaluation and CoMFA/CoMSIA study of nitrofuranyl methyl N-heterocycles as novel antitubercular agents.
    Wang A; Yang Y; Jun Y; Wang B; Lv K; Liu M; Guo H; Lu Y
    Bioorg Med Chem; 2018 May; 26(8):2073-2084. PubMed ID: 29551372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of N-benzyl-5-nitrofuran-2-carboxamide as an antitubercular agent.
    Gallardo-Macias R; Kumar P; Jaskowski M; Richmann T; Shrestha R; Russo R; Singleton E; Zimmerman MD; Ho HP; Dartois V; Connell N; Alland D; Freundlich JS
    Bioorg Med Chem Lett; 2019 Feb; 29(4):601-606. PubMed ID: 30600207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-tubercular agents. Part 8: synthesis, antibacterial and antitubercular activity of 5-nitrofuran based 1,2,3-triazoles.
    Kamal A; Hussaini SM; Faazil S; Poornachandra Y; Narender Reddy G; Kumar CG; Rajput VS; Rani C; Sharma R; Khan IA; Jagadeesh Babu N
    Bioorg Med Chem Lett; 2013 Dec; 23(24):6842-6. PubMed ID: 24206766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Nitrofuran-Warhead-Equipped Spirocyclic Azetidines Show Excellent Activity against
    Komarova K; Vinogradova L; Lukin A; Zhuravlev M; Deniskin D; Chudinov M; Gureev M; Dogonadze M; Zabolotnykh N; Vinogradova T; Lavrova A; Yablonskiy P
    Molecules; 2024 Jun; 29(13):. PubMed ID: 38999023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physicochemical, pharmacokinetic, efficacy and toxicity profiling of a potential nitrofuranyl methyl piperazine derivative IIIM-MCD-211 for oral tuberculosis therapy via in-silico-in-vitro-in-vivo approach.
    Magotra A; Sharma A; Singh S; Ojha PK; Kumar S; Bokolia N; Wazir P; Sharma S; Khan IA; Singh PP; Vishwakarma RA; Singh G; Nandi U
    Pulm Pharmacol Ther; 2018 Feb; 48():151-160. PubMed ID: 29174840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benzimidazole-based compounds kill Mycobacterium tuberculosis.
    Gong Y; Somersan Karakaya S; Guo X; Zheng P; Gold B; Ma Y; Little D; Roberts J; Warrier T; Jiang X; Pingle M; Nathan CF; Liu G
    Eur J Med Chem; 2014 Mar; 75():336-53. PubMed ID: 24556148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and antitubercular evaluation of 4-carbonyl piperazine substituted 1,3-benzothiazin-4-one derivatives.
    Peng CT; Gao C; Wang NY; You XY; Zhang LD; Zhu YX; Xv Y; Zuo WQ; Ran K; Deng HX; Lei Q; Xiao KJ; Yu LT
    Bioorg Med Chem Lett; 2015 Apr; 25(7):1373-6. PubMed ID: 25754492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel 1-(4-substituted benzylidene)-4-(1-(substituted methyl)-2,3-dioxoindolin-5-yl)semicarbazide derivatives for use against Mycobacterium tuberculosis H37Rv (ATCC 27294) and MDR-TB strain.
    Raja S; Prakash CR
    Arch Pharm Res; 2013 Apr; 36(4):411-22. PubMed ID: 23440582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and optimization of benzotriazine di-N-oxides targeting replicating and nonreplicating Mycobacterium tuberculosis.
    Chopra S; Koolpe GA; Tambo-Ong AA; Matsuyama KN; Ryan KJ; Tran TB; Doppalapudi RS; Riccio ES; Iyer LV; Green CE; Wan B; Franzblau SG; Madrid PB
    J Med Chem; 2012 Jul; 55(13):6047-60. PubMed ID: 22691154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel dihydropyrimidines as a potential new class of antitubercular agents.
    Trivedi AR; Bhuva VR; Dholariya BH; Dodiya DK; Kataria VB; Shah VH
    Bioorg Med Chem Lett; 2010 Oct; 20(20):6100-2. PubMed ID: 20813528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 6-hydrogen-8-methylquinolones active against replicating and non-replicating Mycobacterium tuberculosis.
    Tabarrini O; Sabatini S; Massari S; Pieroni M; Franzblau SG; Cecchetti V
    Chem Biol Drug Des; 2012 Nov; 80(5):781-6. PubMed ID: 22889240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and biological evaluation of novel isoniazid derivatives with potent antitubercular activity.
    Martins F; Santos S; Ventura C; Elvas-Leitão R; Santos L; Vitorino S; Reis M; Miranda V; Correia HF; Aires-de-Sousa J; Kovalishyn V; Latino DA; Ramos J; Viveiros M
    Eur J Med Chem; 2014 Jun; 81():119-38. PubMed ID: 24836065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and antitubercular activity of 4-alkoxy-triazoloquinolones able to inhibit the M. tuberculosis DNA gyrase.
    Carta A; Bua A; Corona P; Piras S; Briguglio I; Molicotti P; Zanetti S; Laurini E; Aulic S; Fermeglia M; Pricl S
    Eur J Med Chem; 2019 Jan; 161():399-415. PubMed ID: 30384044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.